BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 18552153)

  • 1. Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors.
    Benz MR; Evilevitch V; Allen-Auerbach MS; Eilber FC; Phelps ME; Czernin J; Weber WA
    J Nucl Med; 2008 Jul; 49(7):1038-46. PubMed ID: 18552153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiation of soft tissue and bone sarcomas from benign lesions utilizing
    Chen B; Feng H; Xie J; Li C; Zhang Y; Wang S
    BMC Med Imaging; 2020 Jul; 20(1):85. PubMed ID: 32711449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials.
    Weber WA; Gatsonis CA; Mozley PD; Hanna LG; Shields AF; Aberle DR; Govindan R; Torigian DA; Karp JS; Yu JQ; Subramaniam RM; Halvorsen RA; Siegel BA; ;
    J Nucl Med; 2015 Aug; 56(8):1137-43. PubMed ID: 25908829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 99mTc-methyl diphosphonate bone scintigraphy and 18F-fluorodeoxyglucose positron emission tomography/computed tomography to predict histologic response to neoadjuvant chemotherapy in patients with osteosarcoma.
    Lee I; Byun BH; Lim I; Kim BI; Kong CB; Song WS; Cho WH; Koh JS; Lim SM
    Medicine (Baltimore); 2018 Sep; 97(37):e12318. PubMed ID: 30212975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymph node standardized uptake values at pre-treatment
    Jeong Y; Baek S; Park JW; Joo JH; Kim JS; Lee SW
    Br J Radiol; 2017 Mar; 90(1071):20160239. PubMed ID: 28008776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake times.
    Liu H; Chen P; Wroblewski K; Hou P; Zhang CP; Jiang Y; Pu Y
    Nucl Med Commun; 2016 Jan; 37(1):50-6. PubMed ID: 26426969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of 3T diffusion-weighted MRI and
    Lee SY; Jee WH; Yoo IR; Jung JY; Im SA; Chung YG; Kang JH
    Br J Radiol; 2019 Oct; 92(1102):20181051. PubMed ID: 31322913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of prone versus supine 18F-FDG-PET of locally advanced breast cancer: Phantom and preliminary clinical studies.
    Williams JM; Rani SD; Li X; Arlinghaus LR; Lee TC; MacDonald LR; Partridge SC; Kang H; Whisenant JG; Abramson RG; Linden HM; Kinahan PE; Yankeelov TE
    Med Phys; 2015 Jul; 42(7):3801-13. PubMed ID: 26133582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reproducibility of [18F]FDG PET/CT liver SUV as reference or normalisation factor.
    Zwezerijnen GJC; Eertink JJ; Ferrández MC; Wiegers SE; Burggraaff CN; Lugtenburg PJ; Heymans MW; de Vet HCW; Zijlstra JM; Boellaard R
    Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):486-493. PubMed ID: 36166080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients.
    Kramer GM; Frings V; Hoetjes N; Hoekstra OS; Smit EF; de Langen AJ; Boellaard R
    J Nucl Med; 2016 Sep; 57(9):1343-9. PubMed ID: 27103020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemotherapy: preclinical evaluation in an orthotopic rat model.
    Dutour A; Decouvelaere AV; Monteil J; Duclos ME; Roualdes O; Rousseau R; Marec-Bérard P
    J Nucl Med; 2009 Sep; 50(9):1533-40. PubMed ID: 19690032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reproducibility of (18)F-FDG PET uptake measurements in head and neck squamous cell carcinoma on both PET/CT and PET/MR.
    Rasmussen JH; Fischer BM; Aznar MC; Hansen AE; Vogelius IR; Löfgren J; Andersen FL; Loft A; Kjaer A; Højgaard L; Specht L
    Br J Radiol; 2015 Apr; 88(1048):20140655. PubMed ID: 25634069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas.
    Benz MR; Allen-Auerbach MS; Eilber FC; Chen HJ; Dry S; Phelps ME; Czernin J; Weber WA
    J Nucl Med; 2008 Oct; 49(10):1579-84. PubMed ID: 18794268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interobserver and intraobserver variability for the assessment of brown adipose tissue activity on 18F-FDG PET-CT.
    Bahler L; Holleman F; Booij J; Hoekstra JB; Verberne HJ
    Nucl Med Commun; 2016 Apr; 37(4):363-71. PubMed ID: 26599066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of response to neoadjuvant chemotherapy in osteosarcoma using dual-phase (18)F-FDG PET/CT.
    Byun BH; Kim SH; Lim SM; Lim I; Kong CB; Song WS; Cho WH; Jeon DG; Lee SY; Koh JS; Chung SK
    Eur Radiol; 2015 Jul; 25(7):2015-24. PubMed ID: 25680716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET.
    Schulte M; Brecht-Krauss D; Werner M; Hartwig E; Sarkar MR; Keppler P; Kotzerke J; Guhlmann A; Delling G; Reske SN
    J Nucl Med; 1999 Oct; 40(10):1637-43. PubMed ID: 10520703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Test-retest repeatability and interobserver variation of healthy tissue metabolism using 18F-FDG PET/CT of the thorax among lung cancer patients.
    Malaih AA; Dunn JT; Nygård L; Kovacs DG; Andersen FL; Barrington SF; Fischer BM
    Nucl Med Commun; 2022 May; 43(5):549-559. PubMed ID: 35081091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas.
    Iagaru A; Masamed R; Chawla SP; Menendez LR; Fedenko A; Conti PS
    Clin Nucl Med; 2008 Jan; 33(1):8-13. PubMed ID: 18097248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.